Electrophilic Multi-Kinase Probes Identify Degradation and Aspartate Conjugation of ULK1
This study introduces a systematic workflow using electrophilic multi-kinase probes to discover ALP-1, a targeted ULK1 degrader that uniquely engages an aspartate residue via chloroacetamide conjugation, thereby revealing new mechanisms for covalent kinase inhibition and degradation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the microscopic world of a living cell, a vast network of proteins acts as the body's internal command center, constantly receiving signals to grow, divide, or repair itself. Among these proteins, a specific family known as kinases functions like molecular switches, turning other proteins on or off by attaching a tiny chemical tag to them. When these switches get stuck in the "on" position, it can lead to diseases like cancer. For decades, scientists have fought these rogue switches by designing drugs that act as reversible inhibitors, essentially jamming the switch so it cannot turn on. However, these jamming drugs often lack the precision to target only the bad switches without affecting the good ones, and they cannot remove the faulty protein entirely. A newer, more aggressive strategy has emerged: instead of just jamming the switch, scientists aim to build a molecular tool that grabs the faulty protein and drags it to the cell's internal recycling plant to be destroyed. This approach, called targeted protein degradation, offers a way to clear the cell of harmful proteins completely, but finding the right tools to do this for every specific protein remains a difficult challenge.
In a recent study, researchers at the University of Dundee set out to discover new ways to degrade a specific protein called ULK1, which serves as a master regulator for a cellular cleanup process known as autophagy. Autophagy is essential for health, but when it malfunctions, it can contribute to neurodegenerative diseases and cancer. The team began by creating a set of "scout" molecules. These were small chemical compounds designed to bind to kinases, but with a twist: they carried a reactive chemical hook on their surface. The idea was that if a scout molecule bound to a kinase, the hook might accidentally snag a nearby part of the protein, triggering a chain reaction that marked the protein for destruction. They tested these scouts on cells and found that one particular molecule successfully caused the levels of ULK1 to drop significantly. This was the first clue that this specific chemical structure could be used to eliminate this specific protein.
The researchers then refined this initial discovery into a more precise tool they named ALP-1. They confirmed that this new molecule did not just block the activity of ULK1; it actually reduced the total amount of the protein in the cell. To understand how this happened, they investigated the cell's waste disposal systems. They found that the degradation did not rely on the proteasome, the cell's primary shredder for unwanted proteins, which is the usual pathway for this type of drug. Instead, the process depended on the lysosome, a different cellular organelle that acts as a digestive sac, and required the activity of an enzyme called E1, which helps tag proteins for removal. This suggested a unique mechanism where the drug was guiding the protein to a different part of the cell's recycling infrastructure.
The most surprising discovery came when the team tried to figure out exactly how ALP-1 grabbed onto ULK1. They expected the chemical hook on the drug, known as a chloroacetamide warhead, to latch onto a sulfur-containing amino acid called cysteine, which is the standard target for this type of chemistry. However, their experiments showed that the hook was not binding to cysteine at all. Through a combination of high-resolution imaging and mass spectrometry, they identified that the hook was actually forming a permanent bond with an aspartate residue, an amino acid that carries a negative charge and is usually not considered reactive enough to be targeted by such drugs. This was a rare and unexpected event, as the chemical hook had managed to attach itself to an acidic part of the protein's surface that sits right at the edge of the protein's active site.
This finding challenges the long-held assumption that these chemical hooks can only react with specific types of amino acids. The researchers demonstrated that the bond formed between the drug and the aspartate residue was strong enough to hold the protein in a way that led to its eventual destruction. They also showed that this degradation was highly specific; when they removed the chemical hook or changed the part of the drug that bound to the protein, the degradation stopped. Furthermore, the drug was able to shut down the signaling pathways controlled by ULK1 much more effectively than a standard inhibitor that merely blocks the protein's activity without removing it. This suggests that completely eliminating the protein is a more powerful way to stop its harmful effects than just turning it off.
The study concludes that by using these scout molecules, scientists can uncover new ways to target proteins that were previously thought to be difficult to degrade. The discovery that a common chemical tool can bind to an aspartate residue opens up new possibilities for designing drugs that can engage a wider range of proteins. While the current tool, ALP-1, is a research instrument rather than a medicine, it proves that the cell's internal machinery can be manipulated in novel ways to remove specific proteins. This work provides a new blueprint for developing therapies that could potentially treat diseases driven by faulty autophagy or other protein-related disorders, by offering a method to clear the cellular landscape of problematic switches entirely.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.